Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline

Launched by TATA MEMORIAL CENTRE · Jan 11, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline," is studying how radiation treatment for certain brain tumors in children and young adults might affect brain function and memory. The researchers want to find out if specific biological markers in the blood and cerebrospinal fluid can help predict any decline in thinking and memory skills that might happen after radiation therapy. They will be looking at 200 participants aged 5 to 39 who have been diagnosed with primary brain tumors and are planning to receive radiation treatment. The goal is to understand how different factors, such as age and the type of radiation used, impact brain function during and after treatment.

Eligible participants will need to have a confirmed diagnosis of a primary brain tumor and a plan for treatment with curative intent radiation. They will also need to provide consent for the study, which may involve additional blood tests during their routine care. Throughout the trial, researchers will monitor both the biological markers and the participants' cognitive abilities using standard intelligence tests. This study aims to improve the quality of life for those undergoing radiation by providing insights that could lead to better support and interventions for managing memory and cognitive health in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 5-39 years
• • 2. Histological diagnosis of primary brain tumor
• • 3. Decision for treatment with radical intent radiotherapy
• • 4. Signed assent and parental consent form for pediatric age group and signed consent form for adults.
• Exclusion Criteria:
• • 1. Inability to undergo neurocognitive evaluation
• • 2. Palliative radiotherapy.
• • 3. Expected life expectancy \< 1 year